Overall survival (OS) in refractory metastatic colorectal cancer (mCRC) improved significantly with the addition of the VEGF ...

Roche’s Tecentriq in combo with Avastin to treat advanced/unresectable hepatocellular carcinoma receives European approval: Basel Tuesday, November 3, 2020, 13:00 Hrs [IST] Roch ...

The opinions expressed herein are the guest's alone and have not been reviewed by a WebMD physician. If you have questions about your health, you should consult your personal physician. This event is ...

The FDA approves Avastin in combination with chemotherapy for patients with platinum-resistant recurrent ovarian cancer, based on results of the phase 3 AURELIA trial. The Food and Drug Administration ...

(CBS/AP) Avastin for breast cancer is out. The FDA says the drug should no longer be used for breast cancer because there's no proof it extends patients' lives - and it causes dangerous side effects.

Intensifying the chemotherapy component of a standard regimen containing Avastin reduced the risk of death and increased five-year overall survival in newly diagnosed metastatic colorectal cancer.

Medicare to continue to cover Avastin for breast cancer treatment, despite FDA. June 30, 2011 — -- Medicare will continue to cover Avastin for breast cancer treatment even if U.S. Food and Drug ...

In November, following an emotional public hearing some months earlier, the Food and Drug Administration withdrew approval for the cancer drug Avastin for patients with metastatic breast cancer — the ...

First, some background. In 2004, the FDA approved Avastin for first-line treatment of patients with metastatic, or malignant, colorectal cancer. The tremendous success of Avastin turned Genentech from ...

SILVER SPRING, Md. - A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way ...

A panel of cancer experts has ruled for a second time that Avastin, the best-selling cancer drug in the world, should no longer be used in breast cancer patients, clearing the way for the U.S.